Patents by Inventor Tobias Koolmeister

Tobias Koolmeister has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted benzodiazoles and use thereof in therapy
    Patent number: 11970474
    Abstract: There is provided herein a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, Y1 to Y4, Z1 to Z3 and n have meanings provided in the description.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 30, 2024
    Assignee: THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING
    Inventors: Armando Cázares-Körner, Thomas Helleday, Torkild Visnes, Olov Wallner, Tobias Koolmeister
  • SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY
    Publication number: 20210002250
    Abstract: There is provided herein a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, Y1 to Y4, Z1 to Z3 and n have meanings provided in the description.
    Type: Application
    Filed: March 1, 2019
    Publication date: January 7, 2021
    Inventors: Armando CÁZARES-KÖRNER, Thomas HELLEDAY, Torkild VISNES, Olov WALLNER, Tobias KOOLMEISTER
  • MTH1 inhibitors for treatment of inflammatory and autoimmune conditions
    Patent number: 10632125
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: April 28, 2020
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Roland Julius Yu Fiskesund
  • MTH1 inhibitors for treatment of cancer
    Patent number: 10179790
    Abstract: A compound of formula I, (I) or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: January 15, 2019
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Sylvain Jacques, Evert Homan, Thomas Helleday
  • Pyrimidine-2,4-diamine derivatives for treatment of cancer
    Patent number: 10174029
    Abstract: A compound of formula I, or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: January 8, 2019
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Thomas Helleday, Tobias Koolmeister, Sylvain Jacques
  • MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS
    Publication number: 20190000856
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    Type: Application
    Filed: August 31, 2018
    Publication date: January 3, 2019
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Roland Julius Yu Fiskesund
  • MTH1 inhibitors for treatment of inflammatory and autoimmune conditions
    Patent number: 10064869
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: September 4, 2018
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Matthieu Desroses, Marie-Caroline Jacques-Cordonnier, Roland Julius Yu Fiskesund
  • PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER
    Publication number: 20180170929
    Abstract: A compound of formula I, or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Application
    Filed: February 19, 2018
    Publication date: June 21, 2018
    Inventors: Martin SCOBIE, THOMAS HELLEDAY, TOBIAS KOOLMEISTER, SYLVAIN JACQUES, MATTHIEU DESROSES, MARIE-CAROLINE JACQUES-CORDONNIER
  • Pyrimidine-2,4-diamine derivatives for treatment of cancer
    Patent number: 9944640
    Abstract: A compound of formula I, or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 17, 2018
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Thomas Helleday, Tobias Koolmeister, Sylvain Jacques, Matthieu Desroses, Marie-Caroline Jacques-Cordonnier
  • HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS
    Publication number: 20170305893
    Abstract: The invention relates to compounds of formula I, or a pharmaceutically-acceptable salt thereof. The present invention also relates to pharmaceutical formulations comprising these compounds, and to their use as medicaments for the treatment of disorders where modulation of DCTPP (deoxycytidine triphosphate pyrophosphatase 1) activity exerts a therapeutic effect.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 26, 2017
    Inventors: Sabin LLONA-MINGUEZ, Andreas HOGLUND, Sylvain JACQUES, Lars JOHANSSON, Tobias KOOLMEISTER, Martin SCOBIE, Thomas HELLEDAY
  • PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER
    Publication number: 20170217961
    Abstract: A compound of formula I, or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Application
    Filed: March 2, 2017
    Publication date: August 3, 2017
    Inventors: MARTIN SCOBIE, THOMAS HELLEDAY, TOBIAS KOOLMEISTER, SYLVAIN JACQUES, MATTHIEU DESROSES, MARIE-CAROLINE JACQUES-CORDONNIER
  • MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS
    Publication number: 20170196873
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.
    Type: Application
    Filed: June 4, 2015
    Publication date: July 13, 2017
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Evert Homan, Thomas Helleday, Sylvain Jacques, Matthieu Desroses, Marie-Caroline Jacques-Cordonnier, Roland Julius Yu Fiskesund
  • MTH1 INHIBITORS FOR TREATMENT OF CANCER
    Publication number: 20170197976
    Abstract: A compound of formula I, (I) or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer.
    Type: Application
    Filed: June 4, 2015
    Publication date: July 13, 2017
    Inventors: Martin Scobie, Olov Wallner, Tobias Koolmeister, Karl Sven Axel Vallin, Carl Martin Henriksson, Sylvain Jacques, Evert Homan, Thomas Helleday
  • Pyrimidine-2,4-diamine derivatives for treatment of cancer
    Patent number: 9604937
    Abstract: A compound of formula (I), or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: March 28, 2017
    Assignee: THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
    Inventors: Martin Scobie, Thomas Helleday, Tobias Koolmeister, Sylvain Jacques
  • Pyrimidine-2,4-Diamine Derivatives for Treatment of Cancer
    Publication number: 20160002175
    Abstract: A compound of formula (I), or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.
    Type: Application
    Filed: November 26, 2013
    Publication date: January 7, 2016
    Inventors: Martin Scobie, Thomas Helleday, Tobias Koolmeister, Sylvain Jacques, Matthieu Desroses, Marie-Caroline Jacques-Cordonnier
  • Inhibitor compounds of semicarbazide-sensitive amine oxidases
    Patent number: 9227967
    Abstract: Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: January 5, 2016
    Assignee: Proximagen Limited
    Inventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister
  • Enzyme inhibitor compounds
    Patent number: 9150574
    Abstract: 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 5-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carbo
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: October 6, 2015
    Assignee: Proximagen Limited
    Inventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister
  • NEW ENZYME INHIBITOR COMPOUNDS
    Publication number: 20140357623
    Abstract: 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 5-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carbo
    Type: Application
    Filed: September 14, 2011
    Publication date: December 4, 2014
    Applicant: PROXIMAGEN LIMITED
    Inventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister
  • New Enzyme Inhibitor Compounds
    Publication number: 20130102587
    Abstract: Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.
    Type: Application
    Filed: March 14, 2011
    Publication date: April 25, 2013
    Applicant: PROXIMAGEN LIMITED
    Inventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister
  • New compounds
    Publication number: 20080103123
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers and N-oxides thereof, wherein one of W1 and W2 is N and the other is CR12. The invention also relates to pharmaceutical compositions comprising these compounds, and to the use of these compounds for the prophylaxis and treatment of medical conditions relating to disorders of the G-protein-coupled receptor GPR119, such as diabetes and obesity.
    Type: Application
    Filed: August 29, 2007
    Publication date: May 1, 2008
    Applicant: Biovitrum
    Inventors: Peter Brandt, Rikard Emond, Gary Johansson, Lars Johansson, Tobias Koolmeister, Bjorn Nilsson, Teresa Sandvall, Michael Weber